Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab tesirine vs Topotecan in DLL3-high SCLC
NCT03061812Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Apr 2017; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03061812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061812.